Fiche publication
Date publication
janvier 2020
Journal
Frontiers in oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DEDIEU Stéphane
,
Dr DEVY Jérôme
,
Dr ETIQUE Nicolas
,
Dr LANGLOIS Benoît
,
Dr SALESSE Stéphanie
,
Dr SCHNEIDER Christophe
Tous les auteurs :
Campion O, Al Khalifa T, Langlois B, Thevenard-Devy J, Salesse S, Savary K, Schneider C, Etique N, Dedieu S, Devy J
Lien Pubmed
Résumé
The low-density lipoprotein receptor (LDLR) family comprises 14 single-transmembrane receptors sharing structural homology and common repeats. These receptors specifically recognize and internalize various extracellular ligands either alone or complexed with membrane-spanning co-receptors that are then sorted for lysosomal degradation or cell-surface recovery. As multifunctional endocytic receptors, some LDLR members from the core family were first considered as potential tumor suppressors due to their clearance activity against extracellular matrix-degrading enzymes. LDLRs are also involved in pleiotropic functions including growth factor signaling, matricellular proteins, and cell matrix adhesion turnover and chemoattraction, thereby affecting both tumor cells and their surrounding microenvironment. Therefore, their roles could appear controversial and dependent on the malignancy state. In this review, recent advances highlighting the contribution of LDLR members to breast cancer progression are discussed with focus on (1) specific expression patterns of these receptors in primary cancers or distant metastasis and (2) emerging mechanisms and signaling pathways. In addition, potential diagnosis and therapeutic options are proposed.
Mots clés
LDLR, biomarker, breast cancer, microenvironment, therapeutic targets
Référence
Front Oncol. 2020 ;10:882
